Drug information provided by: Merative, Micromedex®
Asparaginase Erwinia chrysanthemi recombinant-rywn is used together with other cancer medicines to treat certain types of blood cancer called acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). This medicine is used in patients who have had an allergic reaction to E. coli-derived asparaginase.
Asparaginase Erwinia chrysanthemi recombinant-rywn belongs to the group of medicines known as antineoplastic agents. It interferes with the growth of the cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by this medicine, other effects will also occur. Some of these may be serious and must be reported to your doctor.
Before you begin treatment with Rylaze®, you and your doctor should talk about the benefits of this medicine as well as the risks of using it.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.